DE2449865B2 - Film-shaped medicinal product - Google Patents
Film-shaped medicinal productInfo
- Publication number
- DE2449865B2 DE2449865B2 DE19742449865 DE2449865A DE2449865B2 DE 2449865 B2 DE2449865 B2 DE 2449865B2 DE 19742449865 DE19742449865 DE 19742449865 DE 2449865 A DE2449865 A DE 2449865A DE 2449865 B2 DE2449865 B2 DE 2449865B2
- Authority
- DE
- Germany
- Prior art keywords
- film
- units
- active ingredient
- different
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims description 47
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 5
- 229920003086 cellulose ether Polymers 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 229920002678 cellulose Polymers 0.000 description 16
- 239000001913 cellulose Substances 0.000 description 16
- 235000010980 cellulose Nutrition 0.000 description 16
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- 229960004400 levonorgestrel Drugs 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 10
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 10
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 9
- 229960002568 ethinylestradiol Drugs 0.000 description 9
- -1 Hydroxyalkyl ethers Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- KLCDQSGLLRINHY-UHFFFAOYSA-N 1-phenyldiazenylnaphthalen-2-amine Chemical compound NC1=CC=C2C=CC=CC2=C1N=NC1=CC=CC=C1 KLCDQSGLLRINHY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229920003087 methylethyl cellulose Polymers 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
3030th
Gegenstand der Patentanmeldung P 24 32 925.7-41 sind folienförmige Arzneimittel mit gleichmäßiger Wirkstoffverteilung bzw. folienförmige Placebos auf Basis filmbildender Celluloseäther, dadurch gekennzeichnet, daß sie bis zu 60% Wirkstoffe, ein Trennmittel und als Folienbildner einen nicht-ionogenen, wasserlösliehen Hydroxyalkyläther der Cellulose, Methylcellulose oder Äthylcellulose enthalten sowie ein Verfahren zu deren Herstellung.The subject of the patent application P 24 32 925.7-41 are film-shaped medicaments with more uniform Active ingredient distribution or film-shaped placebos based on film-forming cellulose ethers, characterized in that that they contain up to 60% active ingredients, a release agent and, as a film former, a non-ionic, water-soluble one Hydroxyalkyl ethers of cellulose, methyl cellulose or ethyl cellulose and a method to contain their manufacture.
In Weiterentwicklung des Gegenstandes der Patentanmeldung P 24 32 925.7-41 betrifft die vorliegende Erfindung das in den Ansprüchen näher gekennzeichnete folienförmige Arzneimittel und dessen Herstellung.In a further development of the subject matter of patent application P 24 32 925.7-41 relates to the present Invention, the film-shaped medicament characterized in more detail in the claims and its production.
Es werden in einem Ausstrich Folien hergestellt, die nebeneinander Dosierungseinheiten mit unterschiedlichen Wirkstoffen und/oder verschiedenen Wirkstoffkonzentrationen bzw. Einheiten ohne Wirkstoff aufweisen. Mit Hilfe eines Spezialrakels, das aus zwei oder mehreren Kammern besteht, werden unterschiedliche Lösungen bzw. Suspensionen ohne Vermischen zu einem zusammenhängenden Ausstrich ausgezogen. Die Breite und die Dicke des Ausstrichs ist für jede Kammer separat einstellbar. Gewünschtenfalls können Zonen (Streifen) mit unterschiedlichen Wirkstoffen bzw. verschiedenen Konzentrationen durch unterschiedliche Farbstoffe sichtbar gemacht werden. Durch Trocknung eo des nassen Ausstrichs wird eine Folie erhalten, die bei entsprechender Teilung, zum Beispiel durch Perforation, Einheiten mit unterschiedlichen Wirkstoffen und/oder verschiedenen Wirkstoffkonzentrationen bzw. Einheiten ohne Wirkstoff liefert. Folien mit unterschiedlichen Wirkstoffen und/oder verschiedenen Wirkstoffkonzentrationen werden zur Herstellung von Mehrphasenpräparaten benötigt, beispielsweise zurFoils are produced in a smear that are next to each other with different dosage units Have active ingredients and / or different active ingredient concentrations or units without active ingredient. With the help of a special doctor blade, which consists of two or more chambers, different Solutions or suspensions drawn out into a coherent smear without mixing. the The width and thickness of the smear can be set separately for each chamber. If desired, zones (Strips) with different active ingredients or different concentrations due to different Dyes are made visible. By drying eo the wet smear a film is obtained which at appropriate division, for example by perforation, units with different active ingredients and / or different active ingredient concentrations or units without active ingredient. Slides with different active ingredients and / or different active ingredient concentrations are used for the production of Multi-phase preparations needed, for example for
Herstellung von Präparaten zur Konzeptionsverhütung.Manufacture of contraceptive preparations.
Durch die Möglichkeit der räumlichen Trennung von miteinander inkompatiblen Wirkstoffen in einer Folieneinheit wird die Stabilität der einzelnen Wirkstoffe verbessert.Due to the possibility of spatial separation of incompatible active ingredients in one film unit the stability of the individual active ingredients is improved.
Das folienförmige Arzneimittel enthält ein Trennmittel und als Folienbildner einen nichtionogenen, wasserlöslichen Hydroxyalkyläther der Cellulose, Methylceliulose oder Äthylcellulose.The film-shaped drug contains a release agent and a nonionic, water-soluble film former Hydroxyalkyl ethers of cellulose, methyl cellulose or ethyl cellulose.
Als nichtionogene, wasserlösliche Hydroxyalkyläther der Cellulose seien beispielsweise Hydroxypropylcellulose, Hydroxyäthylcellulose und Methylhydroxypropylcellulose genanntExamples of non-ionic, water-soluble hydroxyalkyl ethers of cellulose are hydroxypropyl cellulose, Hydroxyethyl cellulose and methylhydroxypropyl cellulose called
Geeignete Trennmittel sind u. a. Polyoxyäthylenpolyoxypropylenpolymeres, Polyoxyäthylenstearate, alkyl- bzw. acylsubstituierte Polyadditionsprodukte des Äthylenoxid«, zum Beispiel das Polyadditionsprodukt aus Äthylenoxid und Rizinusöl (40 Mol Äthylenoxid auf 1 Mol Glycerid), Silikone, Silikontrennemulsionen und Metallseifen.Suitable release agents include: Polyoxyethylene polyoxypropylene polymer, Polyoxyethylene stearates, alkyl or acyl-substituted polyadducts of the Ethylene oxide, for example the polyadduct of ethylene oxide and castor oil (40 mol of ethylene oxide 1 mole of glyceride), silicones, silicone release emulsions and metal soaps.
Außer Trennmittel und Folienbildner können die erfindungsgemäßen Folien Füllstoffe und Wirkstoffe enthalten.In addition to release agents and film formers, the films according to the invention can contain fillers and active ingredients contain.
Als Füllstoffe sind zum Beispiel Cellulose, Zucker, wie zum Beispiel Lactose, Dextrose, Rohrzucker usw., Stärken, Mannit, Calciumcarbonat, Calciumphosphat, Talkum und Farbstoffe in löslicher Form oder als Pigmente geeignet Werden lösliche Füll- bzw. Wirkstoff verwendet, entsteht eine transparente, glatte Folie; werden unlösliche Füll- bzw. Wirkstoffe verwendet, entsteht eine weiße oder farbige, papierartige Folie.As fillers, for example, cellulose, sugar, such as lactose, dextrose, cane sugar, etc., Starches, mannitol, calcium carbonate, calcium phosphate, talc and dyes in soluble form or as Pigments suitable If soluble fillers or active ingredients are used, a transparent, smooth film is created; if insoluble fillers or active ingredients are used, a white or colored, paper-like film is created.
Es können alle in der Human- und Veterinärmedizin verwendeten Wirkstoffe eingesetzt werden. Für die innere Anwendung kommt insbesondere die orale Verabreichung in Frage. Unter der äußeren Anwendung sollen insbesondere die topikale Verabreichung auf der Haut und in Körperhöhlungen wie Nase, Ohr, Vagina usw, verstanden werden. Als Wirkstoffe seien beispielsweise genannt: Gestagene, östrogene, Gemische aus Gestagenen und östrogenen, Tranquilizer, Antidiabetika, Sulfonamide, Antibiotika, Trichomonadenmittel, Entzündungshemmer, wie zum Beispiel Corticoide, usw.All active ingredients used in human and veterinary medicine can be used. For the internal use, in particular, is oral administration. Under the external application are intended in particular for topical administration on the skin and in body cavities such as the nose, ear, vagina etc, to be understood. Examples of active ingredients are: gestagens, estrogens, mixtures of Progestins and estrogens, tranquilizers, antidiabetic drugs, Sulphonamides, antibiotics, trichomonads, anti-inflammatories such as corticoids, etc.
Der Arzneimittelwirkstoff kann im Trägermaterial gelöst oder gleichmäßig suspendiert vorliegen. Der Wirkstoffanteil in der Folie kann 0 — 60% betragen. Als Einzeldosis (Einheit) werden Flächen geschnitten bzw. perforiert, die Wirkstoffmengen enthalten, wie sie üblicherweise auch in Tabletten, Dragoes, Salben, Zäpfchen usw. enthalten sind. So kann die Wirkstoffmenge pro Einzeldosis je nach Anwendungsart beliebig hoch sein und zwischen etwa 1 μg und 0,5 g betragen, wobei die untere und obere Dosis leicht unter- oder überschritten werden können. Selbstverständlich können auch wirkstofffreie Träger (Placebos) hergestellt werden.The active pharmaceutical ingredient can be dissolved or evenly suspended in the carrier material. Of the Active ingredient content in the film can be 0 - 60%. As a single dose (unit), areas are cut or perforated, which contain amounts of active ingredient, as is usually found in tablets, dragoes, ointments, Suppositories, etc. are included. The amount of active ingredient per single dose can be as desired, depending on the type of application be high and between about 1 μg and 0.5 g, the lower and upper dose can easily be exceeded or fallen below. Of course you can drug-free carriers (placebos) can also be produced.
Zur Herstellung des folienförmigen Arzneimittels mit unterschiedlichen Wirkstoffen und/oder verschiedenen Wirkstoffkonzentrationen werden zwei oder mehrere unterschiedliche Lösungen bzw. Suspensionen aus Trennmittel, Folienbildner und gegebenenfalls Füllstoffen und/oder Wirkstoffen bereitet, die unterschiedlichen Lösungen bzw. Suspensionen mit Hilfe eines Spezialrakels, das aus zwei oder mehreren Kammern besteht, auf einer Folienziehmaschine zu einem Ausstrich ausgezogen und die durch Trocknung des Ausstrichs erhaltene Folie in Einheiten mit unterschiedlichen Wirkstoffen und/oder verschiedenen Wirkstoffkonzentrationen bzw. Einheiten ohne Wirkstoff geteilt.For the production of the film-shaped medicament with different active ingredients and / or different Active ingredient concentrations are made up of two or more different solutions or suspensions Release agents, film formers and optionally fillers and / or active ingredients prepare the different Solutions or suspensions with the help of a special doctor blade, which consists of two or more chambers a film drawing machine drawn out to form a smear and that obtained by drying the smear Foil in units with different active ingredients and / or different active ingredient concentrations or units divided without active ingredient.
Pro Lösung bzw. Suspension wird der Folienbildner in Gewichtsmengen von 6-20%, der Füllstoff in Gewichtsmengen von 0-30% und das Trennmittel vorzugsweise in Gewichtsmengen von 0,01 -2% eingesetzt The film former is used for each solution or suspension in Amounts by weight of 6-20%, the filler in amounts by weight of 0-30% and the release agent preferably used in amounts by weight of 0.01-2%
Das Lösungs- bzw. Suspensionsmittel ist zu etwa 48-84 Gewichtsprozent enthalten und besteht aus Wasser und/oder einem oder mehreren organischen Lösungsmitteln. Als organische Lösungsmittel kommen physiologisch verträgliche Lösungsmittel oder solche Lösungsmittel in Betracht, die bei der Trocknung bis auf einen physiologisch unbedenklichen Rest entfernt werden können. Solche Lösungsmittel sind zum Beispiel Äthylalkohol, Isopropanol, Methylenchlorid usw. und ihre Mischungen. Wasser und Äthylalkohol bzw. Gemische aus Wasser und Äthylalkohol werden bevorzugt angewandtThe solvent or suspending agent is about 48-84 percent by weight and consists of Water and / or one or more organic solvents. Come as organic solvents Physiologically acceptable solvents or those solvents that are up to during drying a physiologically harmless residue can be removed. Such solvents are for example Ethyl alcohol, isopropanol, methylene chloride, etc. and their mixtures. Water and ethyl alcohol or mixtures of water and ethyl alcohol are used preferably applied
Die Schichtdicke des nassen Ausstrichs beträgt etwa 0,1—2 mm und die der trockenen Folie etwa 0,05—1 mm, vorzugsweise0,07—03 mm.The layer thickness of the wet smear is about 0.1-2 mm and that of the dry film about 0.05-1 mm, preferably 0.07-03 mm.
Das kontinuierliche Verfahren zur Herstellung des folienförmigen Arzneimittels bietet den Vorteil, daß der Wirkstoff homogen und gleichmäßig verteilt in dem Wirkstoffträger vorliegt Durch die Konzentration des Wirkstoffs im Träger, die Dicke der Folie und die Fläche der Folie kann man die Einzeldosis sehr einfach variieren.The continuous process for the production of the film-shaped medicament has the advantage that the The active ingredient is homogeneously and evenly distributed in the active ingredient carrier by the concentration of the Active ingredient in the carrier, the thickness of the film and the area of the film can be the single dose very easily vary.
Zusammensetzung für je eine Einheit: Teil 1 (wirkstoflhaltig)Composition for one unit each: Part 1 (contains active ingredients)
Teil 2 (wirkstofffrei)Part 2 (drug-free)
Beispiel 1
Zweiphasenpräparatexample 1
Two-phase preparation
Teil 1: 21 Einheiten mit Wirkstoff
Teil 2: 7 Einheiten ohne WirkstoffPart 1: 21 units with active ingredient
Part 2: 7 units without active ingredient
Herstellung für 3000 Einheiten Teil 1Manufacture for 3000 units part 1
0,75 g D-Norgestrel,0.75 g D-norgestrel,
0,15 g Äthinylöstradiol und0.15 g ethinyl estradiol and
0,54 g Polyoxyäthylenpolyoxypropylenpolymeres0.54 g of polyoxyethylene polyoxypropylene polymer
werden in einer Mischung aus
237,00 g Äthylalkohol und
12,00 g Wasser gelöst. In diese Lösung werden
44,28 g Hydroxypropylcellulose und
44,28 g Cellulose eingetragen und gegebenenfalls homogenisiert.be in a mix of
237.00 g of ethyl alcohol and
12.00 g of water dissolved. Be in this solution
44.28 g of hydroxypropyl cellulose and
44.28 g of cellulose entered and, if necessary, homogenized.
Herstellung für 1000 Einheiten Teil 2Manufacture for 1000 units part 2
0,18 g Polyoxyäthylenpolyoxypropylenpolymeres0.18 g of polyoxyethylene polyoxypropylene polymer
werden in einer Mischung aus
79,00 g Äthylalkohol und
4,00 g Wasser gelöst. In diese Lösung werden
14,91 g Hydroxypropylcellulose und
14,91 g Cellulose eingetragen und gegebenenfalls homogenisiert.be in a mix of
79.00 g of ethyl alcohol and
4.00 g of water dissolved. Be in this solution
14.91 g of hydroxypropyl cellulose and
14.91 g of cellulose entered and optionally homogenized.
Die so erhaltenen Suspensionen werden auf einem geeigneten Folienziehgerät mit einem Zweikammer-Spezialrakel (Breite der Kammern: 1=54 mm; 2=18 mm) zu einem Ausstrich von 0,5 mm ausgezogen und anschließend getrocknet. Bei entsprechender Teilung in Einheiten zu 18x18 mm, zum Beispiel durch Perforation, können über die Breite der Folie drei Einheiten mit Wirkstoff und eine wirkstofffreie Einheit abgeteilt werden. Aus dem Folienband lassen sich nun beliebig viele Abschnitte im Verhältnis von drei Einheiten mit Wirkstoff und einer Einheit ohne Wirkstoff herstellen.The suspensions obtained in this way are applied to a suitable film drawing device with a two-chamber special doctor blade (Width of the chambers: 1 = 54 mm; 2 = 18 mm) pulled out to a smear of 0.5 mm and then dried. With the appropriate Division in units of 18x18 mm, for example through Perforation, there can be three units with active ingredient and one unit without active ingredient across the width of the film be divided. Any number of sections in a ratio of three can now be made from the foil strip Create units with active ingredient and one unit without active ingredient.
0,25 rag D-Norgestrel0.25 rag D-norgestrel
0,05 mg Äthinylöstradiol0.05 mg ethinyl estradiol
14,76 mg Hydroxypropylcellulose 14,91 mg14.76 mg hydroxypropyl cellulose 14.91 mg
14,76 mg Cellulose 14,91 mg14.76 mg cellulose 14.91 mg
0,18 mg Polyoxyäthylenpolyoxy- 0,18 mg0.18 mg polyoxyethylene polyoxy 0.18 mg
propylenpolymeres propylene polymer
30,00 mg Gewicht pro Einheit 30,00 mg30.00 mg Weight per unit 30.00 mg
Fläche pro Einheit: ca.3 cm2.
Aussehen: weiß.Area per unit: about 3 cm 2 .
Appearance: white.
Beispiel 2
Dreiphasenpräparet (Zweiwirkstoff stuf enpräparat)Example 2
Three-phase preparation (two-agent stage preparation)
Teil 1:11 Einheiten mit 0,05 mg D-NorgestrelPart 1: 11 units with 0.05 mg D-norgestrel
0,05 mg Äthinylöstradiol
Teil 2:10 Einheiten mit 0,125 mg D-Norgestrel0.05 mg ethinyl estradiol
Part 2: 10 units with 0.125 mg D-norgestrel
0,050 mg Äthinylöstradiol
Teil 3: 7 Einheiten ohne Wirkstoff0.050 mg ethinyl estradiol
Part 3: 7 units without active ingredient
Herstellung für 1100 Einheiten Teil 1:Manufacture for 1100 units part 1:
0,055 g D-Norgestrel,
0,055 g Äthinylöstradiol und
0,198 g Polyoxyäthylenpolyoxypropylenpolymeres0.055 g D-norgestrel,
0.055 g ethinyl estradiol and
0.198 g of polyoxyethylene polyoxypropylene polymer
werden in einer Mischung aus
86,900 g Äthylalkohol und
4,400 g Wasser gelöst In diese Lösung werden
16346 g Hydroxypropylcellulose und
16,346 g Cellulose eingetragen und gegebenenfalls homogenisiertbe in a mix of
86,900 g of ethyl alcohol and
4,400 g of water are dissolved in this solution
16346 g of hydroxypropyl cellulose and
16.346 g of cellulose entered and optionally homogenized
Herstellung für 1000 Einheiten Teil 2:Production for 1000 units part 2:
0,125 g D-Norgestrel,
0,050 g Äthinylöstradiol und0.125 g D-norgestrel,
0.050 g ethinyl estradiol and
0,180 g Polyoxyäthylenpolyoxypropylenpolymeres0.180 g of polyoxyethylene polyoxypropylene polymer
werden in einer Mischung aus
79,000 g Äthylalkohol und
4,000 g Wasser gelöst In diese Lösung werden
14,823 g Hydroxypropylcellulose undbe in a mix of
79,000 g of ethyl alcohol and
4,000 g of water are dissolved in this solution
14.823 g of hydroxypropyl cellulose and
14,822 g Cellulose eingetragen und gegebenenfalls homogenisiert14.822 g of cellulose entered and optionally homogenized
Herstellung für 700 Einheiten Teil 3:Production for 700 units part 3:
so 0,189 g Polyoxyäthylenpolyoxypropylenpolymeresso 0.189 g of polyoxyethylene polyoxypropylene polymer
werden in einer Mischung aus
82,950 ggÄthylalkohol und
4,200 g Wasser gelöst In diese Lösung werden
15,656 g Hydroxypropylcellulose und
15,655 g Cellulose eingetragen und gegebenenfalls homogenisiert.be in a mix of
82,950 ggethyl alcohol and
4.200 g of water are dissolved in this solution
15.656 g of hydroxypropyl cellulose and
15.655 g of cellulose entered and optionally homogenized.
Die so erhaltenen Suspensionen werden auf einem geeigneten Folienziehgerät mit einem Dreikammer-Spezialrakel (Breite pro Kammer 18 mm) zu einem Ausstrich ausgezogen und getrocknet. Bei entsprechender Teilung, zum Beispiel durch Perforation, zu Einheiten von 18 χ 18 mm für Teil 1, 18 χ 19,8 mm für Teil 2 und 18 χ 28 mm für Teil 3 können über die Breite der Folie drei Einheiten mit unterschiedlichem Wirkstoffgehalt abgeteilt werden. Aus dem Folienband lassen sich Präparate mit 11 Einheiten Teil 1, 10 Einheiten Teil 2 und 7 Einheiten Teil 3 abtrennen.The suspensions obtained in this way are applied to a suitable film drawing device with a three-chamber special doctor blade (Width per chamber 18 mm) pulled out into a smear and dried. With the appropriate Division, for example by perforation, into units of 18 χ 18 mm for part 1, 18 χ 19.8 mm for Part 2 and 18 χ 28 mm for part 3 can have three units with different active ingredient content across the width of the film be divided. Preparations with 11 units part 1, 10 Separate units part 2 and 7 units part 3.
Zusammensetzung pro Einheit:
Teil 1 Teil 2Composition per unit:
Part 1 Part 2
Teil 3part 3
InhaltsstofTeIngredients
Teil 1:11 Einheiten mit 0,05 mg D-NorgestrelPart 1: 11 units with 0.05 mg D-norgestrel
0,05 mg Äthinylörtradiol0.05 mg ethynyl ortradiol
Teil 2: 10 Einheiten mit 0,125 mg D-NorgestrelPart 2: 10 units with 0.125 mg D-norgestrel
0,050 mg Äthinylöstradiol0.050 mg ethinyl estradiol
Teil 3: 7 Einheiten mit 50,00 mg Eisen(II)fumaratPart 3: 7 units with 50.00 mg iron (II) fumarate
Herstellung für 1100 Einheiten Teil 1:Manufacture for 1100 units part 1:
0,066 g Lebensmittelgelb Nr. 2 (Tartrazin; E 102) werden in0.066 g of Food Yellow No. 2 (tartrazine; E 102) are used in
4,400 g Wasser gelöst und anschließend in 86,900 ggÄthylalkohol eingetragen. In dieser Lösung werdenDissolved 4,400 g of water and then added to 86,900 g of ethyl alcohol. In this solution will
0,055 g D-Norgestrel,
0,055 g Äthinylöstradiol und
0,198 g Polyoxyäthylenpolyoxypropylenpolymeres gelöst.0.055 g D-norgestrel,
0.055 g ethinyl estradiol and
0.198 g of polyoxyethylene polyoxypropylene polymer dissolved.
In diese Lösung werden
16,313 g Hydroxypropylcellulose und
16,313 g Cellulose eingetragen und gegebenenfalls homogenisiertBe in this solution
16.313 g of hydroxypropyl cellulose and 16.313 g of cellulose are added and optionally homogenized
Herstellung für 1000 Einheiten Teil 2:Production for 1000 units part 2:
0,065 g Lebensmittelorange Nr. 2 (Sunset Yellow; E 110) werden in0.065 g of food orange No. 2 (Sunset Yellow; E 110) are in
4,000 g Wasser gelöst und anschließend in 79,000 ggÄthylalkohol eingetragen. In dieser Lösung werdenDissolved 4,000 g of water and then added to 79,000 g of ethyl alcohol. In this solution will
0,125 g D-Norgestrel,
0,050 g Äthinylöstradiol und0.125 g D-norgestrel,
0.050 g ethinyl estradiol and
D-No/gestre!D-No / gestre!
ÄthinylöstradiolEthinyl estradiol
PolyoxyäthylenpolyoxypropylenpolymeresPolyoxyethylene polyoxypropylene polymer
HydroxypropylcelluloseHydroxypropyl cellulose
CelluloseCellulose
Gewicht pro EinheitWeight per unit
Fläche pro EinheitArea per unit
AussehenAppearance
0,180 g Polyoxyäthylenpolyoxypropylenpolymeres0.180 g of polyoxyethylene polyoxypropylene polymer
gelöstsolved
In diese Lösung werden
14,790 g Hydroxypropylcellulose und
14,790 g Cellulose eingetragen und gegebenenfalls homogenisiertBe in this solution
14.790 g of hydroxypropyl cellulose and
14.790 g of cellulose entered and optionally homogenized
Herstellung für 700 Einheiten Teil 3:Production for 700 units part 3:
0,042 g Saccharin,0.042 g saccharin,
0,042 g Sahne-Essenz und0.042 g cream essence and
0,406 g Polyoxyäthylenpolyoxypropylenpolymeres
werden in einer Mischung aus0.406 g of polyoxyethylene polyoxypropylene polymer
be in a mix of
55300 gÄthylalkohol und55300 ethyl alcohol and
2,800 g Wasser gelöst In diese Lösung werden
35,000 g Eisen(II)fumarat
17,50Og Hydroxypropylcellulose,2.800 g of water are dissolved in this solution
35,000 g iron (II) fumarate
17.50Og hydroxypropyl cellulose,
5,950 g Kakao und5.950 g cocoa and
4,060 g Cellulose eingetragen und gegebenenfalls homogenisiertEntered 4.060 g of cellulose and, if necessary, homogenized
Die so erhaltenen Suspensionen werden auf einem geeigneten Folienziehgerät mit einem Dreikammer-Spezialrakel (Breite pro Kammer 18 mm) zu einem Ausstrich ausgezogen und anschließend getrocknet Bei entsprechender Teilung, zum Beispiel durch Perforation, zu Einheiten von 18 χ 18 mm für Teil 1, χ 19,8 mm für Teil 2 und 18 χ 28 mm für Teil 3 können über die Breite der Folie drei Einheiten mit unterschiedlichem Wirkstoffgehalt abgeteilt werden. Aus dem Folienband lassen sich Präparate mit 11 Einheiten Teil 1, Einheiten Teil 2 und 7 Einheiten Teil 3 abtrennen.The suspensions obtained in this way are applied to a suitable film drawing device with a three-chamber special doctor blade (Width per chamber 18 mm) pulled out into a smear and then dried appropriate division, e.g. by perforation, in units of 18 χ 18 mm for part 1, χ 19.8 mm for part 2 and 18 χ 28 mm for part 3 can have three units with different sizes across the width of the film Active ingredient content are divided. Preparations with 11 units part 1, Separate units part 2 and 7 units part 3.
Claims (2)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19742449865 DE2449865B2 (en) | 1974-10-17 | 1974-10-17 | Film-shaped medicinal product |
| IN993/CAL/1975A IN142428B (en) | 1974-07-05 | 1975-05-19 | |
| AU82527/75A AU493703B2 (en) | 1975-06-08 | A pharmaceutical preparation inthe form ofa foil having an active substance incorporated therein | |
| FI751801A FI60354C (en) | 1974-07-05 | 1975-06-17 | FOERFARANDE FOER FRAMSTAELLNING AV LAEKEMEDEL I FOLIEFORM |
| JP50078601A JPS6028810B2 (en) | 1974-07-05 | 1975-06-24 | Manufacturing method of pharmaceutical oil |
| IL47573A IL47573A (en) | 1974-07-05 | 1975-06-26 | Pharmaceutical preparation in the form of a foil having an active substance incorporated therein |
| RO7582701A RO68836A (en) | 1974-07-05 | 1975-06-30 | PROCEDURE FOR CONDITIONING A PHARMACEUTICAL PHARMACEUTICAL PHARMACEUTICAL MEDICINE IN WATER OR ORGANIC SOLVENTS |
| NLAANVRAGE7507785,A NL186294C (en) | 1974-07-05 | 1975-06-30 | METHOD FOR THE MANUFACTURE OF A FOIL-like MEDICINAL PREPARATION |
| DK295075A DK143221C (en) | 1974-07-05 | 1975-06-30 | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL MEDICINE FOR ORAL OR TOPICAL USE |
| PH17340A PH18973A (en) | 1974-07-05 | 1975-07-02 | A pharmaceutical preparation in the form of a foil having an active substance incorporated therein |
| EG382A EG11756A (en) | 1974-07-05 | 1975-07-02 | Medicament carriers in the form of foil having active substance incorporated therein |
| DD187079A DD122196A5 (en) | 1974-07-05 | 1975-07-03 | |
| CH870075A CH625704A5 (en) | 1974-07-05 | 1975-07-03 | Pharmaceutical composition in sheet form |
| IE1474/75A IE42604B1 (en) | 1974-07-05 | 1975-07-03 | A pharmaceutical preparation in the form of a foil having an active substance incorporated therein |
| SE7507659-6A SE413285B (en) | 1974-07-05 | 1975-07-03 | PROVIDED TO MANUFACTURE A PHARMACEUTICAL CARRIER IN FILM FORM WITH INCORPORATED ACTIVE SUBSTANCE |
| NO752416A NO752416L (en) | 1974-07-05 | 1975-07-03 | |
| CA230,802A CA1067407A (en) | 1974-07-05 | 1975-07-04 | Pharmaceutical preparation in the form of a foil having an active substance incorporated therein |
| GB28252/75A GB1510999A (en) | 1974-07-05 | 1975-07-04 | Pharmaceutical preparation in the form of a foil having an active substance incorporated therein |
| FR7521022A FR2276811A1 (en) | 1974-07-05 | 1975-07-04 | SHEETS SERVING AS SUPPORTS FOR ACTIVE MEDICINAL SUBSTANCES |
| US05/707,032 US4136145A (en) | 1974-07-05 | 1976-07-20 | Medicament carriers in the form of film having active substance incorporated therein |
| US05/865,080 US4136162A (en) | 1974-07-05 | 1977-12-27 | Medicament carriers in the form of film having active substance incorporated therein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19742449865 DE2449865B2 (en) | 1974-10-17 | 1974-10-17 | Film-shaped medicinal product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2449865A1 DE2449865A1 (en) | 1976-04-29 |
| DE2449865B2 true DE2449865B2 (en) | 1981-06-19 |
Family
ID=5928736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19742449865 Withdrawn DE2449865B2 (en) | 1974-07-05 | 1974-10-17 | Film-shaped medicinal product |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE2449865B2 (en) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19745208A1 (en) * | 1997-10-13 | 1999-04-15 | Labtec Gmbh | Pharmaceutical film that dissolves in mouth |
| DE19856101A1 (en) * | 1998-12-04 | 2000-06-08 | Labtec Gmbh | Patch for local administration of drugs in the oral cavity includes a drug-containing matrix comprising a water-insoluble cellulose ether and a water-soluble cellulose ether in a defined ratio |
| DE19900645A1 (en) * | 1999-01-11 | 2000-07-13 | Deotexis Inc | Transdermal therapeutic system, has drug release matrix on base foil subdivided into unit dose portions allowing selection of dose by patient |
| DE10213772A1 (en) * | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Cohesive unit of singular transdermal therapeutic systems |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US7910641B2 (en) | 2001-10-12 | 2011-03-22 | Monosol Rx, Llc | PH modulated films for delivery of actives |
| US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| US8652378B1 (en) | 2001-10-12 | 2014-02-18 | Monosol Rx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US9108340B2 (en) | 2001-10-12 | 2015-08-18 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US10034833B2 (en) | 2009-08-07 | 2018-07-31 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US10272607B2 (en) | 2010-10-22 | 2019-04-30 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US11077068B2 (en) | 2001-10-12 | 2021-08-03 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US11191737B2 (en) | 2016-05-05 | 2021-12-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6185315A (en) * | 1984-10-04 | 1986-04-30 | Teikoku Seiyaku Kk | Sheet-form preparation |
| JPS61280423A (en) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | Mucosal application agent in oral cavity |
| DE3630603A1 (en) * | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES, REAGENTS OR THE LIKE, AND METHOD FOR THE PRODUCTION THEREOF |
| DE19646392A1 (en) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery |
| DE19652257A1 (en) | 1996-12-16 | 1998-06-18 | Lohmann Therapie Syst Lts | Individually dosed, film-like dosage form that quickly disintegrates on contact with liquid and contains active ingredients and especially flavorings |
| US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
| PT1471893E (en) | 2002-01-25 | 2007-02-28 | Lohmann Therapie Syst Lts | Method and device for producing products in web form |
| CA2505796C (en) | 2002-07-22 | 2012-01-03 | Monosolrx Llc | Packaging and dispensing of rapid dissolve dosage form |
| WO2007056066A2 (en) | 2005-11-04 | 2007-05-18 | Lifescience Plus, Inc. | Bioabsorbable hemostatic gauze |
| US9265779B2 (en) | 2008-05-13 | 2016-02-23 | Lts Lohmann Therapie-Systeme Ag | Method of using a film-shaped preparation comprising oily substances for oral administration |
| DE102008023345B4 (en) | 2008-05-13 | 2014-12-04 | Lts Lohmann Therapie-Systeme Ag | Film-like preparation with oily substances for oral administration |
| AU2011265294B2 (en) | 2010-06-10 | 2015-01-22 | Aquestive Therapeutics, Inc. | Nanoparticle film delivery systems |
| US12465564B2 (en) | 2021-10-25 | 2025-11-11 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617282A1 (en) * | 1965-11-30 | 1975-02-06 | Astra Pharma Prod | DEVICE FOR LOCAL ANESTHETIZATION BY LOCAL APPLICATION AND METHOD FOR MANUFACTURING THIS DEVICE |
| NL6902314A (en) * | 1969-02-13 | 1970-08-17 |
-
1974
- 1974-10-17 DE DE19742449865 patent/DE2449865B2/en not_active Withdrawn
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19745208A1 (en) * | 1997-10-13 | 1999-04-15 | Labtec Gmbh | Pharmaceutical film that dissolves in mouth |
| DE19856101A1 (en) * | 1998-12-04 | 2000-06-08 | Labtec Gmbh | Patch for local administration of drugs in the oral cavity includes a drug-containing matrix comprising a water-insoluble cellulose ether and a water-soluble cellulose ether in a defined ratio |
| DE19900645A1 (en) * | 1999-01-11 | 2000-07-13 | Deotexis Inc | Transdermal therapeutic system, has drug release matrix on base foil subdivided into unit dose portions allowing selection of dose by patient |
| DE19900645C2 (en) * | 1999-01-11 | 2003-03-20 | Deotexis Inc | Transdermal therapeutic system |
| US8906277B2 (en) | 2001-10-12 | 2014-12-09 | Monosol Rx, Llc | Process for manufacturing a resulting pharmaceutical film |
| US9855221B2 (en) | 2001-10-12 | 2018-01-02 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US7824588B2 (en) | 2001-10-12 | 2010-11-02 | Monosol Rx, Llc | Method of making self-supporting therapeutic active-containing film |
| US7910641B2 (en) | 2001-10-12 | 2011-03-22 | Monosol Rx, Llc | PH modulated films for delivery of actives |
| US11077068B2 (en) | 2001-10-12 | 2021-08-03 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US10888499B2 (en) | 2001-10-12 | 2021-01-12 | Aquestive Therapeutics, Inc. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US8652378B1 (en) | 2001-10-12 | 2014-02-18 | Monosol Rx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US9108340B2 (en) | 2001-10-12 | 2015-08-18 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US9931305B2 (en) | 2001-10-12 | 2018-04-03 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| DE10213772A1 (en) * | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Cohesive unit of singular transdermal therapeutic systems |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US10111810B2 (en) | 2002-04-11 | 2018-10-30 | Aquestive Therapeutics, Inc. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US11135216B2 (en) | 2009-08-07 | 2021-10-05 | Indivior Uk Limited | Sublingual and buccal film compositions |
| US10821074B2 (en) | 2009-08-07 | 2020-11-03 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| US9687454B2 (en) | 2009-08-07 | 2017-06-27 | Indivior Uk Limited | Sublingual and buccal film compositions |
| US10034833B2 (en) | 2009-08-07 | 2018-07-31 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US10940626B2 (en) | 2010-10-22 | 2021-03-09 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
| US10272607B2 (en) | 2010-10-22 | 2019-04-30 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
| US11191737B2 (en) | 2016-05-05 | 2021-12-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2449865A1 (en) | 1976-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2449865B2 (en) | Film-shaped medicinal product | |
| DE2432925C3 (en) | Film-shaped medicinal products | |
| CH625704A5 (en) | Pharmaceutical composition in sheet form | |
| DE60006692T2 (en) | PHARMACEUTICAL COMBINATION OF ETHINYLESTRADIOL AND DROSPIRENONE AS A CONCEPT OF PREPARATION | |
| DE2418345C2 (en) | Pharmaceutical agent for external use on human skin | |
| DE60127134T2 (en) | NEW COMPOSITION FOR TRANSDERMAL AND / OR TRANSMUCOSAL ACTIVE INGREDIENT USE WITH APPROPRIATE THERAPEUTIC MIRROR | |
| DE2012775C3 (en) | Ointment foils and process for their manufacture | |
| DE69611978T2 (en) | Multi-layer film preparation | |
| DE60130147T2 (en) | USE OF ORAL FORMULATIONS TO TREAT THE FEMALE SEXUAL DISORDER | |
| US4136145A (en) | Medicament carriers in the form of film having active substance incorporated therein | |
| DE68926122T2 (en) | TRANSDERMAL ESTROGEN / PROGESTINE DOSING UNIT AND SYSTEM. | |
| EP0148724B1 (en) | Sequential combined multiphase preparation and its use for oral contraception | |
| DE2207294C2 (en) | Topical ointment base | |
| WO2002005789A2 (en) | Solution-, dispersion- or emulsion-producing film dermatics | |
| DE3045634A1 (en) | PHARMACEUTICAL PREPARATION WITH SLOW RELEASE OF ACTIVE SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF | |
| EP0814776A1 (en) | Topically applied pharmaceutical composition, method of preparing it and its use | |
| DE102007011486A1 (en) | Medicament comprising at least one progestin | |
| DE2057957A1 (en) | New means for the production of an aqueous preparation for cosmetic purposes | |
| DE3612305A1 (en) | LIQUID MEDICINE FOR THERAPY OF PSORIASIS BASED ON FILM-FORMING POLYMERS | |
| DE69922684T2 (en) | USE OF 2-METHOXYESTRADIOL AS FUNGICIDES | |
| DE3414629A1 (en) | Composition with pharmaceutical action, therapeutic use of the composition and process for its preparation | |
| DE2309202A1 (en) | MEDICINAL FORMS WITH MICRO-ENCAPSULATED MEDICINAL ACTIVE | |
| DE60003943T2 (en) | TRIMEGESTONE CONTAINING PHARMACEUTICAL COMPOSITIONS | |
| DE2356098B2 (en) | Composition for envelopes | |
| DE2631448A1 (en) | MULTIPLE TABLETS AND THE METHOD OF MANUFACTURING THEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AF | Is addition to no. |
Ref country code: DE Ref document number: 2432925 Format of ref document f/p: P |
|
| 8230 | Patent withdrawn |